What We Do

Brava Diagnostics is developing a portfolio of in vitro diagnostic tests for medical settings where lab-quality results are vital in making time-critical decisions.

  • Cardiac Markers: This product line includes point-of-care tests for high-sensitivity troponin for heart attack, NT-proBNP for heart failure and D-dimer for clotting.
  • Host-Response: The Brava™ Host-Response Panels will measure biomarkers that appear early in acute phase infections to help assess the cytokine storm that is associated with bad outcomes.
  • COVID-19: The Brava™ COVID-19 Antibody Panel helps to determine a person’s exposure to SAR-CoV-2 and potential immunity.


Brava Diagnostics is assembling a world-class management team, scientists, board of directors and scientific advisory board. We are located in Boulder, Colorado. The combination of a thriving life science sector, awesome natural beauty and outstanding opportunities for outdoor activities makes Boulder a draw for top-notch talent.


Byron Hewett, Co-Founder and CEO

Byron has led healthcare and life science companies for more than 30 years, in multi-national firms, development-stage and start-up companies. Byron is a 4-time CEO, including Brava Diagnostics. Prior to Brava, Byron was CEO of SomaLogic, a life sciences tools company focused on biomarker discovery. He raised $240M, grew revenues from $11M-$30M and increased staff from 95 to 195. Byron served as Chairman and CEO of BioBehavioral Diagnostics, a start-up medical device company with the first FDA-cleared system for the assessment of ADHD. He served as chief executive officer and a director at Immunicon Corporation (NASDAQ: IMMC), the first FDA-cleared test for circulating tumor cells (CTC). He served in executive roles at Qiagen, Bayer Diagnostics, Chiron Diagnostics and Abbott Laboratories.

Byron earned a Masters in Management degree from Northwestern University's J.L. Kellogg Graduate School of Management and a Bachelor’s of Science degree from the University of Virginia's McIntire School of Commerce.


David Okrongly, Ph.D., Co-Founder and Chief Operating Officer

Dave has been a business executive and R&D leader in the diagnostics industry, ranging from start-up to multi-national companies. He brings expertise in instrument and assay development, clinical/regulatory affairs and operations. Prior to joining Brava, Dave served as President of the OPKO Diagnostics division of OPKO Health, Inc. (NASDQ: OPK). He led the development and launch of the 4Kscore test for aggressive prostate cancer risk determination, and the development of the FDA-approved Claros 1 point-of-care analyzer. He served as chief operating officer of Exosome Diagnostics, President and CEO for Quanterix Corporation (NASDQ: QTRX), and held leadership positions with Siemens and Bayer Diagnostics.

Dave earned his PhD in Chemistry from Columbia University and a BSc with honors in Chemistry from the University of Wisconsin-Madison.


Carrie Mulherin, Co-Founder and Chief Marketing Officer

Carrie is a marketing and sales executive with extensive start-up experience and 31 product launches. Carrie brings deep experience in strategic marketing, cross-functional team management and commercialization. Carrie was CEO of Focus Marketing, an independent consulting agency, VP of Diagnostics at SomaLogic, VP of Marketing and Sales for BioBDx/Pearson, Director of Marketing for Orasure Technologies, VP of Marketing and Sales at Immunicon Corporation and VP Sales and Marketing at Intracel Corporation.

Carrie earned a bachelor’s degree in molecular biology and biochemical sciences from Princeton University and an MBA in marketing from the University of Scranton.

Scientific Advisory Board

Fred Apple, PhDHennepin Co Medical Center, Hennepin Healthcare Research Institute (HHRI)Co-Director Clinical & Forensic Toxicology Laboratory. Principal Investigator, Cardiac Biomarkers Trials Laboratory. Professor, Laboratory Medicine & Pathology, University of Minnesota.
Judd Hollander, MDThomas Jefferson UniversitySVP of Healthcare Delivery Innovation. Associate Dean for Strategic Health Initiatives. Vice Chair of Finance and Healthcare Enterprises, Dept of Emergency Medicine.
Allan Jaffe, MDMayo ClinicChair of the Division of Clinical Core Laboratory Services in the Department of Laboratory Medicine and Pathology
Frank Peacock, MDBaylor College of MedicineAssociate Chair of Emergency Medicine. Founding member/ past President and Chief Medical Officer of the Accreditation Management Board of the American College of Cardiology.
Nelson Trujillo, MDBoulder Community HealthInterventional Cardiologist
Alan Wu, PhDUCSFProfessor, Laboratory Medicine. Co-core lab director, Zuckerberg San Francisco General Hospital.
Richard Zane, MDUniversity of Colorado School of MedicineChair of the Department of Emergency Medicine. Chief Innovation Officer for UCHealth

Board of Directors

Robert J. Silverman, Chairman of the Board and Independent Director

Robert J. Silverman is the Board Chairman for Brava Diagnostics. Bob currently serves in a Board and Advisory capacity to a portfolio of companies including MBio Diagnostics, Kiyatec Inc., Lophius Biosciences GmbH, Pathovax LLC and Gilde Healthcare Venture Partners.

He served as the CEO of mtm laboratories AG, an in-vitro diagnostics company that developed and commercialized a portfolio of products for the early detection and diagnosis of cervical cancer. Bob was instrumental in raising capital and building mtm laboratories into a global, fully-integrated commercial business. He led the company to a $240 Million exit to Roche Diagnostics. Prior to leading mtm laboratories, he held senior executive positions at Viacell, Cytyc Corporation, Pasteur Merieux and Abbott Laboratories Pharmaceuticals.

He earned his Master’s Degree in Marketing and Finance from the Kellogg Graduate School of Management at Northwestern University. Bob received his B.S. in Pharmacy from the University of Michigan.

Byron Hewett, Chief Executive Officer, Brava Diagnostics

Christopher J. Myatt, Ph.D. Chief Executive Officer, MBio Diagnostics

Dr. Myatt is the founder and CEO of MBio Diagnostics, Inc. He is an entrepreneur with a proven track record for building technology companies, securing patents and licensing technology, raising funding, establishing commercial operations, and leading through growth. Prior to MBio Diagnostics, Chris successfully founded and led Precision Photonics Corporation, a successful laser and optical technology supplier that is now a division of IDEX. Trained as a physicist and measurement scientist, Chris invented and developed multiple technologies that formed the basis of his companies.

Chris earned a B.S. in Physics and a B.A. in Mathematics at Southern Methodist University. Chris also earned a Ph.D. in Atomic Physics at the University of Colorado. He studied Bose-Einstein Condensation (BEC) under Carl Wieman (Nobel Prize, 2001), helping to create the first BEC condensate in the Wieman lab. He also studied quantum information under David Wineland (Nobel Prize, 2012) as a National Research Council (NRC) Postdoctoral Fellow at the National Institute of Standards and Technology (NIST) in Boulder.

Learn More about the Team

Read short biographies on the executive team and Board.

Download our Fact Sheet

Download a 2-page summary about our strategy.

Schedule a Meeting

Brava is currently raising seed financing. Let's talk!